Current management and new approaches in the treatment of APL.
Tallman
Martin S
MS
Northwestern University, USA.
D000617:Aminoglycosides / Q000494:pharmacology; D018943:Anthracyclines / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000639:trends; D016903:Drug Monitoring; D000079982:Gemtuzumab; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000628:therapy*; D010087:Oxides / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D033581:Stem Cell Transplantation; D014212:Tretinoin / Q000008:administration & dosage
D000617:Aminoglycosides; D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000079982:Gemtuzumab; D000077237:Arsenic Trioxide